TY - JOUR
T1 - Importance of minimal residual disease in hairy cell leukemia
T2 - Monoclonal antibodies as a therapeutic strategy
AU - Thomas, Deborah A.
AU - Ravandi, Farhad
AU - Keating, Michael
AU - Kantarjian, Hagop M.
PY - 2009
Y1 - 2009
N2 - With the use of nucleoside analogs as frontline therapy, the prognosis of hairy cell leukemia HCL has improved dramatically. Unfortunately, disease recurrence remains problematic. Eradication of minimal residual disease MRD persisting after therapy may further improve outcome. The evolution of available techniques used to assess MRD, and the potential incorporation of novel agents such as monoclonal antibodies MoAbs into the treatment armamentarium for HCL mandate that MRD analyses be performed concurrently with routine assessments of disease status. Herein, the available data regarding the prevalence and clinical relevance of MRD after therapy for HCL is reviewed.
AB - With the use of nucleoside analogs as frontline therapy, the prognosis of hairy cell leukemia HCL has improved dramatically. Unfortunately, disease recurrence remains problematic. Eradication of minimal residual disease MRD persisting after therapy may further improve outcome. The evolution of available techniques used to assess MRD, and the potential incorporation of novel agents such as monoclonal antibodies MoAbs into the treatment armamentarium for HCL mandate that MRD analyses be performed concurrently with routine assessments of disease status. Herein, the available data regarding the prevalence and clinical relevance of MRD after therapy for HCL is reviewed.
KW - Minimal residual disease
KW - Prognosis
KW - Rituximab
UR - http://www.scopus.com/inward/record.url?scp=70449358326&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70449358326&partnerID=8YFLogxK
U2 - 10.3109/10428190903142224
DO - 10.3109/10428190903142224
M3 - Review article
C2 - 19814695
AN - SCOPUS:70449358326
SN - 1042-8194
VL - 50
SP - 27
EP - 31
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - SUPPL. 1
ER -